搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
The American Journal of Managed Care
10 天
Sarepta Halts Development, Testing of DMD Therapy SRP-5051
Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...
BioSpace
5 天
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
9 天
on MSN
Sarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy Now
We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...
5 天
Mutual of America Capital Management LLC Sells 2,579 Shares of Sarepta Therapeutics, Inc ...
Mutual of America Capital Management LLC cut its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) ...
Yahoo Finance
12 天
Why Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They Seem
To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Sarepta Therapeutics has an accrual ratio of 0.79 for the year to September 2024.
4 天
Buy Rating for Sarepta Therapeutics: Significant Pipeline Potential and Strategic Growth ...
Analyst Luke Sergott of Barclays maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $209.00.Don't ...
MarketWatch
2 天
Sarepta Therapeutics Inc.
Dyne Therapeutics Inc.-0.13% $3.03B ...
5 天
Buy Rating on Sarepta Therapeutics: Confidence in Elevidys’ Market Potential and ...
In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...
6 天
Piper称Sarepta股票前景强劲,竞争对手展示早期DMD数据
周二,Piper Sandler维持对Sarepta Therapeutics (NASDAQ:SRPT)股票的增持评级,目标价保持在$200.00。该公司的立场是在竞争对手RGNX披露其用于杜氏肌营养不良症(DMD)的基因疗法RGX-202的最新进展之后做出的,该疗法正在进入关键性试验阶段。 更新内容包括研究第1/2阶段首五名患者的初步功能数据,显示功能改善和良好的安全性,未报告严重不良事件(S ...
Muscular Dystrophy News
12 天
Sarepta stops development of exon 51-skipping therapy for DMD
Sarepta has stopped developing SRP-5051, its exon 51-skipping therapy for Duchenne MD, due to long-term safety concerns and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈